Blog Portal

Fiscal Sustainability Report 2018

Report to be published.

PBO's Approach to Measuring Potential GDP

This report describes PBO’s approach to measuring potential GDP.

Status Report on Phase 1 of the Investing in Canada Plan

This report a status update on Phase 1 of the Government’s Investing in Canada Plan, which was announced in Budget 2016 and intended to provide a short-term economic boost to the economy.

Extended April 2018 Economic and Fiscal Outlook

In preparation for the financial costing of election campaign proposals in 2019, the PBO is taking this opportunity to produce an extended outlook and line-item costing. The PBO encourages parliamentarians and their political parties to provide feedback regarding this initiative.

2017-18 Report on the Activities of the Office of the Parliamentary Budget Officer

2017-18 Report on the Activities of the Office of the Parliamentary Budget Officer

Taxation of employer-provided health-benefits - Report revised June 1, 2018

The PBO has prepared an estimate of the fiscal impact of including employer-paid health benefits in an individual’s taxable income.

The Impact of a Pan-Canadian Carbon Pricing Levy on PBO’s GDP Projection

This report provides additional detail related to the economic impact of the carbon pricing levy presented in PBO’s April 2018 Economic and Fiscal Outlook.
 

Cost Estimate for Bill C-394: An Act to amend the Income Tax Act (parenting tax credit)

Consistent with PBO’s mandate, this report estimates the net fiscal cost resulting from an implementation of a private member’s bill, Bill C-394 which amends the Income Tax Act to establish a tax credit with respect to maternal and parental benefits, and would "provide a tax credit that would offset any taxes owing on their maternity and parental leave."

The Government’s Expenditure Plan and Main Estimates 2018-19

This note examines the federal government’s Expenditure Plan and Main Estimates for 2018-19, which supports the second appropriation bill that will seek Parliament’s approval of $112.9 billion.

Patent restoration and the cost of pharmaceuticals

This report pulls together a number of databases so as to estimate the cost of recent regulatory changes governing patented pharmaceuticals. It compares the cost of patented innovative medicines with that of non-patented prescription medicines. That comparison is then used to make inferences regarding the annual cost of prolonging market exclusivity for a class of drugs similar to patented innovative medicines.

About

Menu

Content

Contact Us

50 O'Connor Street, Suite 919
Ottawa, Ontario
K1A 0A9

Google not found location by address.